MedMined and BD HealthSight alternatives for antimicrobial stewardship, infection surveillance and antibiograms

BD HealthSight competitors compared

Every product below is described only from its vendor's public pages, read in September 2026. Where a vendor does not state something publicly, the table says so. Antimicrobe is not affiliated with BD, Wolters Kluwer, Inovalon, Premier or Epic.

If you need HAI surveillance, compare the platforms

Infection Advisor does something Antimicrobe does not: it watches microbiology, lab and pharmacy data for patterns that mark a likely healthcare-associated infection, alerts the infection preventionist, and streamlines HAI submissions to NHSN. If that workflow is why you bought MedMined, your real alternatives are the other surveillance platforms, and the evaluation looks like any enterprise software selection.

Sentri7 is the obvious first call. Wolters Kluwer sells Sentri7 Infection Prevention and Sentri7 Pharmacy Surveillance on one platform, and KLAS named them the 2026 Best in KLAS in infection control and monitoring and in pharmacy surveillance. VigiLanz, now owned by Inovalon, sells Infection Prevention alongside its tiered Pharmacy Surveillance product. TheraDoc from Premier covers both surveillance and stewardship alerts for acute and post-acute care. If you run Epic, Bugsy is already certified for AUR reporting, and the question becomes whether your analysts have the build time.

None of these vendors publishes a price, so the only way to compare is to ask each for a quote with the same scope: facility count, interface list, which modules, implementation fee, and the annual license.

We have written separate comparisons for each: Sentri7 alternatives and competitors, VigiLanz alternatives by tier, and TheraDoc competitors.

If you need the antibiogram, you may not need a platform

Clinical Advisor gives stewardship pharmacists benchmarks: how your resistance and antimicrobial use compare with similar facilities, regionally and nationally. That is useful for a committee slide. It is not the document a prescriber opens at 2 a.m. to pick empiric therapy for a urinary source on 4 West. That document is the cumulative antibiogram, built from your own isolates under CLSI M39 rules, and in most hospitals someone still builds it by hand once a year.

Antimicrobe does only that job and does it from the file your lab already exports. You upload a CSV with seven fields (patient key, collection date, specimen source, unit, organism, antibiotic, S, I or R result). It keeps the first isolate per patient per organism per period, marks any cell with fewer than 30 isolates, and produces the facility antibiogram with cuts by source and unit, quarterly trends and empiric options ranked by local susceptibility. No HL7 interface, no EHR project, no IT ticket.

Every limit is on the antimicrobial stewardship software pricing page, and the hospital antibiogram page shows what the finished report looks like.

• Lab plan, $249 a month: one facility, 25,000 isolates a year, 2 seats, bought by card
• Stewardship plan, $749 a month: up to 3 facilities, unit and syndrome cuts, quarterly trends, MDRO watch
• Network plan, $2,400 a month: up to 12 facilities compared side by side, scheduled LIS export ingest

Keep BD HealthSight and move the antibiogram out

Many hospitals should not rip out Infection Advisor. If the infection preventionists rely on its alerts and NHSN workflow, replacing it is a year of work and a real risk to surveillance continuity. The narrower move is to keep the BD Advisors for what they do well and stop paying people to build the antibiogram by hand beside them.

That setup is simple because the two never touch. Antimicrobe reads a susceptibility export from the lab, not from BD, so there is nothing to interface and nothing for BD to approve. The stewardship pharmacist keeps working the Clinical Advisor alert queue, and the antibiogram, its unit cuts and the quarterly trend come from a separate report that takes minutes to refresh when the next export lands.

What to check before you leave BD HealthSight

Switching surveillance vendors fails in predictable places. Before a contract ends, confirm each of these in writing.

• Historical data: how many years of HAI events, alerts and interventions you can export, and in what format
• NHSN continuity: who submits HAI and AUR data for the months the two systems overlap
• Interfaces: which of your lab, pharmacy and ADT feeds the new vendor needs, and who builds them
• Custom rules: every alert your team wrote in Clinical Advisor has to be rebuilt and re-validated
• Benchmarks: the regional and national comparison is BD's data; check what the replacement offers instead
• Contract links: whether the Advisors are priced as part of a wider Pyxis or Alaris agreement

Who should stay on BD HealthSight

A health system that runs Pyxis and Alaris house-wide, uses HealthSight Diversion Management, and has infection preventionists working Infection Advisor daily gets real value from one vendor holding all of that data. The benchmarking in Clinical Advisor is also hard to replicate: no small vendor, Antimicrobe included, has regional and national comparison data from BD's installed base. For that hospital, the right question is not which platform replaces BD, but whether the antibiogram is still being built by hand next to it.